Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.

Zinkstok SM, Roos YB; ARTIS investigators.

Lancet. 2012 Aug 25;380(9843):731-7. doi: 10.1016/S0140-6736(12)60949-0. Epub 2012 Jun 28.

PMID:
22748820
2.

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.

Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sandercock P, Hacke W; Stroke Thrombolysis Trialists' Collaborative Group.

Lancet. 2014 Nov 29;384(9958):1929-35. doi: 10.1016/S0140-6736(14)60584-5. Epub 2014 Aug 5. Review.

3.

A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial.

Zinkstok SM, Vermeulen M, Stam J, de Haan RJ, Roos YB; ARTIS study group.

Trials. 2010 May 12;11:51. doi: 10.1186/1745-6215-11-51.

4.

Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.

Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, Ford I, Muir KW.

Lancet Neurol. 2015 Apr;14(4):368-76. doi: 10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26.

PMID:
25726502
5.

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators.

N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.

6.

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.

Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G.

Lancet. 2010 May 15;375(9727):1695-703. doi: 10.1016/S0140-6736(10)60491-6.

PMID:
20472172
7.

Antithrombotic drugs and ischaemic stroke.

[No authors listed]

Prescrire Int. 2013 Nov;22(143):270-1.

PMID:
24427842
9.

Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.

Torgano G, Zecca B, Monzani V, Maestroni A, Rossi P, Cazzaniga M, Manganaro D, Boiti C, Zilioli E, Borutti G, Falaschi F, Mandelli C.

Cerebrovasc Dis. 2010 Feb;29(3):275-81. doi: 10.1159/000275503. Epub 2010 Jan 15.

PMID:
20090319
10.

Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.

Bluhmki E, Chamorro A, Dávalos A, Machnig T, Sauce C, Wahlgren N, Wardlaw J, Hacke W.

Lancet Neurol. 2009 Dec;8(12):1095-102. doi: 10.1016/S1474-4422(09)70264-9. Epub 2009 Oct 21.

PMID:
19850525
11.

Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis.

Bravo Y, Martí-Fàbregas J, Cocho D, Rodríguez-Yáñez M, Castellanos M, de la Ossa NP, Roquer J, Obach V, Maestre J, Martí-Vilalta JL.

Cerebrovasc Dis. 2008;26(2):126-33. doi: 10.1159/000139659. Epub 2008 Jun 17.

PMID:
18560215
12.

Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT).

Mori E, Minematsu K, Nakagawara J, Yamaguchi T; Japan Alteplase Clinical Trial (J-ACT) Group.

J Stroke Cerebrovasc Dis. 2011 Nov;20(6):517-22. doi: 10.1016/j.jstrokecerebrovasdis.2010.04.001. Epub 2010 Aug 17.

PMID:
20719535
13.

Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.

Wahlgren N, Ahmed N, Dávalos A, Hacke W, Millán M, Muir K, Roine RO, Toni D, Lees KR; SITS investigators.

Lancet. 2008 Oct 11;372(9646):1303-9. doi: 10.1016/S0140-6736(08)61339-2. Epub 2008 Sep 12.

PMID:
18790527
14.

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P.

Lancet. 1998 Oct 17;352(9136):1245-51.

PMID:
9788453
16.

Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis.

Dorado L, Millán M, de la Ossa NP, Guerrero C, Gomis M, López-Cancio E, Ricciardi AC, Dávalos A.

Eur J Neurol. 2010 Feb;17(2):301-6. doi: 10.1111/j.1468-1331.2009.02843.x. Epub 2009 Nov 12.

PMID:
19912320
17.

Early deterioration after thrombolysis plus aspirin in acute stroke: a post hoc analysis of the Antiplatelet Therapy in Combination with Recombinant t-PA Thrombolysis in Ischemic Stroke trial.

Zinkstok SM, Beenen LF, Majoie CB, Marquering HA, de Haan RJ, Roos YB.

Stroke. 2014 Oct;45(10):3080-2. doi: 10.1161/STROKEAHA.114.006268. Epub 2014 Aug 19.

18.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A.

Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Erratum in: Lancet. 2012 Aug 25;380(9843):730.

19.

Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial.

Zinkstok SM, Vermeulen M, Stam J, de Haan RJ, Roos YB.

Cerebrovasc Dis. 2010;29(1):79-81. doi: 10.1159/000256651. Epub 2009 Nov 10.

PMID:
19907167
20.

Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.

Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, Wahlgren N, Ahmed N; SITS Investigators.

Stroke. 2012 Jun;43(6):1524-31. doi: 10.1161/STROKEAHA.111.644815. Epub 2012 Mar 22. Erratum in: Stroke. 2012 Sep;43(9):e102.

Supplemental Content

Support Center